MMP9 and obesity due to melanocortin 4 receptor deficiency: Given the demonstrated ability of ITE to suppress LPS-induced MMP-9 expression through the inhibition of NF-κB and AP-1 signaling, future studies will explore its therapeutic potential in in vivo models of obesity-associated inflammation.